en · de · es · fr · pt
lab-handbook.peptides3081.com › Topic › Research Claims And Evidence Status — Quick Reference

Research Claims And Evidence Status — Quick Reference

By Editorial Desk · published 2025-11-23 · last reviewed 2025-12-24 · Topic

The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.

Research Claims and Evidence Status

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.

Structure, Naming and Discovery

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Epitalon at a glance

PropertyValueNotes
Regulatory statusNot an approved drugMarketed in most countries as a research chemical
Main literature languageRussian and EnglishEarly reports concentrated in Russian journals
Typical stated purity≥95% by HPLCSupplier declaration, seldom independently verified
Principal studied endpointTelomerase activity in vitroMeasured in cultured human cells
Reported administration routesSubcutaneous, intranasalDescribed in exploratory use reports

Epitalon in Research Literature and Handling

Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.

Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.

Related pages on this site

Epitalon Structure and Research Origin

Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.

(TG:@pojiaai)Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.

Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.

Analytical Characterization and Stability

Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.

Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.

Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.

Reference notes

Diagnosis is made with reasonable certainty based on history and clinical examination. X-rays may confirm the diagnosis. The typical changes seen on X-ray include: joint space narrowing, subchondral sclerosis (increased bone formation around the joint), subchondral cyst formation, and osteophytes. The combination of knee pain and osteophytes on x-ray or hip pain and osteophytes on x-ray, has good sensitivity and specificity for the diagnosis of osteoarthritis of those joints. X-rays may not correlate with the findings on physical examination or with the degree of pain, especially in the early course of osteoarthritis, where imaging findings may be relatively normal. In 1990, the American College of Rheumatology, using data from a multi-center study, developed a set of criteria for the diagnosis of hand osteoarthritis based on hard tissue enlargement and swelling of certain joints. These criteria were found to be 92% sensitive and 98% specific for hand osteoarthritis versus other entities such as rheumatoid arthritis and spondyloarthropathies.

The complete laboratory synthesis of B12 was achieved by Robert Burns Woodward and Albert Eschenmoser in 1972. The work required the effort of 91 postdoctoral fellows (mostly at Harvard) and 12 PhD students (at ETH Zurich) from 19 nations. The synthesis constitutes a formal total synthesis, since the research groups only prepared the known intermediate cobyric acid, whose chemical conversion to vitamin B12 was previously reported. This synthesis of vitamin B12 is of no practical consequence due to its length, taking 72 chemical steps and giving an overall chemical yield well under 0.01%. Although there have been sporadic synthetic efforts since 1972, the Eschenmoser–Woodward synthesis remains the only completed (formal) total synthesis.

The column was adapted for the 2004 TV series House M.D., for which Sanders served as a medical consultant for the show. Her work also has resulted in a documentary series. A Netflix documentary series titled Diagnosis was released in August 2019. Produced by the New York Times, each episode follows Dr. Lisa Sanders as she seeks to diagnose patients with difficult symptoms. In addition to writing a column for The New York Times, Sanders has written 4 books related to medicine.

Sources: en.wikipedia.org

Reference notes

In a lecture on 14 September 2007, Dietmar von Reeken described the emergence of a "Lower Saxony consciousness" in the 19th century, the geographical basis of which was used to invent a territorial construct: the resulting local heritage societies (Heimatvereine) and their associated magazines routinely used the terms "Lower Saxony" or "Lower Saxon" in their names. At the end of the 1920s in the context of discussions about a reform of the Reich, and promoted by the expanding local heritage movement (Heimatbewegung), a 25-year conflict started between "Lower Saxony" and "Westphalia". The supporters of this dispute were administrative officials and politicians, but regionally focussed scientists of various disciplines were supposed to have fuelled the arguments. In the 1930s, a real Lower Saxony did not yet exist, but there were a plethora of institutions that would have called themselves "Lower Saxon". The motives and arguments in the disputes between "Lower Saxony" and "Westphalia" were very similar on both sides: economic interests, political aims, cultural interests and historical aspects.

== Career == McLain provides voices for many characters in several video games from Valve. Among them are GLaDOS, the primary antagonist of the Portal video game series (for which she won an AIAS Interactive Achievement Award for Outstanding Achievement in Character Performance), the announcer in Team Fortress 2, and the voice of the Combine Overwatch for the Half-Life series. McLain sang "Still Alive" and "Want You Gone", the ending credits songs to Portal and Portal 2, respectively, both of which were written by Jonathan Coulton. She also sang "Cara Mia Addio" at the end of Portal 2. In December 2011, McLain won the Spike Video Game Award in the category "Best Performance by a Human Female" for her voice acting as GLaDOS in Portal 2. In 2013, she lent her public support to gathering donations for the Kickstarter-funded LGBT gaming convention GaymerX. She later was a special guest at the convention in August 2013. In 2014, she portrayed Fairy Godmother in the online video series [Wish It Inc.]. In 2015, she portrayed Lisa Clarke in the gay independent film, Winning Dad. This film was also promoted on McLain's YouTube channel. McLain has played roles in many radio dramas on the radio program Imagination Theatre. In 2021, McLain provided the voice of GLaDOS non-canonically, singing a verse in The Chalkeaters’ song "Count to Three" as a cameo.

In 1979, a possible association between autism and opioids was proposed, it was noted that injecting small amounts of opiates into young laboratory animals resulted in symptoms similar to those seen in autistic children. The possibility of a relationship between autism and the consumption of gluten and casein was first articulated by Kalle Reichelt in 1991. Opiate theory hypothesizes that autism is the result of a metabolic disorder in which opioid peptides gliadorphin (aka gluteomorphin) and Casomorphin, produced through metabolism of gluten (present in wheat and related cereals) and casein (present in dairy products), pass through an abnormally permeable intestinal wall and then proceed to exert an effect on neurotransmission through binding with opioid receptors. It has been postulated that the resulting excess of opioids affects brain maturation and causes autistic symptoms including: behavioral difficulties, attention problems, and alterations in communicative capacity and social and cognitive functioning. Although high levels of these opioids are eliminated in the urine, it has been suggested that a small part of them cross into the brain causing interference of signal transmission and disruption of normal activity. Three studies have reported that urine samples of people with autism show an increased 24-hour peptide excretion. A study with a control group found no appreciable differences in opioid levels in urine samples of people with autism compared to controls. Two studies showed an increased opioid levels in cerebrospinal fluid of people with autism.

His funeral in Medellín drew crowds of mourners and prompted national reflection on the violence surrounding the game. Humberto Muñoz Castro, a bodyguard employed by the alleged drug trafficker Santiago Gallón, confessed to the shooting and was sentenced to 43 years' imprisonment, of which he served eleven; investigators discounted early suggestions that gambling syndicates had ordered the killing, though the theory persisted.

Sources: en.wikipedia.org

Reference notes

== Gene == The gene that codes for pancreatic elastase 1 is CELA1 (synonym: ELA1) Pancreatic elastase 1 is encoded by a single genetic locus on chromosome 12. Studies of human pancreatic elastase 1 have shown that this serine protease maps to the chromosomal region 12q13 and it is close to a locus for an autosomal dominant skin disease, Diffuse nonepidermolytic palmoplantar keratoderma.

==== Hypothetical: With Great Yarmouth First ==== A poll was commissioned for the constituency of Great Yarmouth for a new (although unregistered at the time) party "Great Yarmouth First" led by Rupert Lowe, prior to the formation of Restore Britain. The sample size of this poll was significantly smaller than standard polling leading to a wider margin of error. Great Yarmouth First was registered with the Electoral Commission as a political party on 4 March 2026.

== Life and career == Jack Donald Lennart Bergagård was born in Öckerö on 13 February 1936. In the late 1950s Bergagård was employed as a pastor in the Pentecostal congregation Elim in Örebro. After visiting Aage Samuelsen's Maran Ata meetings in Oslo in 1959, he resolved to spread the movement in Sweden, becoming one of the founders of the Maranata movement there. He founded the first Swedish Maranata congregation in Örebro in 1960. He was one of the founders of Maran Ata in Oslo, where he was also a pastor from 2001 to 2004. Later that year, he moved to the United States. Bergagård wrote the Swedish text to the song där rosor aldrig dör/Till en stad jag är på vandring, dit där rosor aldrig dör. The tune was written by Jack & Jim Elsie, under the original title I am going to a city, where the roses never fade. In March 1963, Bergagård led a Maran Ata meeting in Jönköping, where a 13-year-old boy with diabetes was prayed for. His parents withdrew his insulin shots; the boy died a week later, drawing media attention. Bergagård died on 29 September 2026, at the age of 90.

Sources: en.wikipedia.org

Frequently asked questions

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

What is the strongest evidence for its activity?

The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.

Why is epitalon sold online?

It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.

What is epitalon made of?

It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.

Network